(AP) A panel of respiratory experts has voted in favor of approving an experimental inhaler drug from GlaxoSmithKline and Theravence for treating chronic lung disease. A majority of Food and Drug ...
WASHINGTON (AP) — The Food and Drug Administration says it has approved a new once-a-day inhaler drug from GlaxoSmithKline for patients with chronic lung disease. The agency cleared the Breo Ellipta ...
The FINANCIAL — GlaxoSmithKline plc and Theravance, Inc. on April 30 announced that the US Food and Drug Administration (FDA) has approved BREO ELLIPTA (fluticasone furoate/vilantero for the ...
today announced that the Pulmonary-Allergy Drugs Advisory Committee (PADAC) to the US Food and Drug Administration (FDA) voted that the efficacy and safety data provide substantial evidence to support ...
TRENTON, N.J. (AP) — The Food and Drug Administration has approved the first inhaler combining three medicines to ease breathing in patients with emphysema or chronic bronchitis. The FDA late Monday ...
DUBLIN--(BUSINESS WIRE)--The "Global BREO Ellipta Drugs Market Report and Forecast 2023-2031" report has been added to ResearchAndMarkets.com's offering. The global BREO ellipta drugs market is driven ...
GSK plc GSK announced plans to cap out-of-pocket expenses for its inhaled respiratory portfolio in the United States at $35 per month, following a similar move by rivals AstraZeneca AZN and Boehringer ...
Adherium, a New Zealand-based maker of connected respiratory medical devices, has received the US Food and Drug Administration's 510(k) clearance for connecting its digital monitoring platform with ...
Transpire Bio was hit with a patent and trademark infringement lawsuit on Sept. 25 in Florida Southern District Court over its proposed generic version of the 'BREO ELLIPTA' inhaler. The action, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback